RenovoRx (NasdaqCM:RNXT) Conference Transcript

Summary of RenovoRx Conference Call - December 09, 2025 Company Overview - Company: RenovoRx Inc. (NasdaqCM:RNXT) - Industry: Cancer therapeutics and medical devices Key Points and Arguments 1. New Approach to Cancer Treatment: RenovoRx is focusing on localizing therapy for cancers rather than solely targeting tumors, aiming to minimize patient toxicity while effectively treating cancer [2][3] 2. Commercialization of RenovoCath Device: The company has initiated the commercialization of its FDA-cleared RenovoCath device, generating over $900,000 in revenue year-to-date through Q3 2025 without a dedicated sales infrastructure [3][4] 3. Market Potential: The peak revenue potential for the RenovoCath device in the U.S. is estimated at over $400 million, based on indications and areas of use [4][12] 4. TAMP Mechanism: The proprietary Trans-Arterial Micro-Perfusion (TAMP) mechanism allows for localized chemotherapy delivery, significantly increasing drug concentration at the tumor site while reducing systemic exposure [5][8][9] 5. Clinical Trials: The pivotal phase III TIGeR-PaC study for locally advanced pancreatic cancer is progressing, with enrollment expected to complete in early 2026 and final data anticipated in 2027 [5][18] 6. Patient Experience: The TAMP procedure is outpatient, requiring only conscious sedation, and allows patients to receive treatment in about 90 minutes, contrasting with traditional chemotherapy that often requires longer hospital stays [10][11] 7. Market Expansion: Beyond pancreatic cancer, the device is applicable to other hypovascular tumors, including cholangiocarcinoma and non-small cell lung cancers, which could further expand the market [11][34] 8. Sales Infrastructure: A lean sales team has been established, with 14 centers approved to purchase the device and five actively using it, indicating strong initial market interest [14][15][26] 9. Financial Position: As of Q3 2025, RenovoRx reported over $10 million in cash and anticipates revenue growth in 2026, with a current cash burn of approximately $800,000 per month [24][34] 10. Reimbursement and Margins: The company has established reimbursement rates allowing for device pricing between $6,000 and $8,500, with current margins around 80%, expected to improve as manufacturing scales [12][35] Additional Important Content - Regulatory Pathway: The device was approved through the 510(k) pathway, allowing for a faster and simpler regulatory process compared to more invasive technologies [28][29] - International Market Considerations: While there is potential for international expansion, the focus remains on the U.S. market due to higher reimbursement rates and lower regulatory hurdles [28][29] - Future Collaborations: Ongoing discussions with medical device companies for potential partnerships or distribution arrangements are in place, indicating interest in the device's unique capabilities [37][38] - Scientific Advisory Board: The company has a strong advisory board with notable experts in oncology, enhancing its credibility and potential for clinical success [22] This summary encapsulates the key insights from the RenovoRx conference call, highlighting the company's innovative approach to cancer treatment, market potential, and strategic plans for growth.